Who Owns Abrysvo?
Abrysvo is owned by Pfizer Inc. (NYSE: PFE), a publicly traded American pharmaceutical company headquartered in New York City. Abrysvo is a recombinant protein vaccine against respiratory syncytial virus, first approved by the FDA in May 2023 for adults 60 and older, expanded to maternal immunization in August 2023 and to younger at-risk adults in 2024.
Abrysvo Timeline
GlobalOfficial Website
Who Owns Abrysvo?
- Parent Company: Pfizer Inc.
- Ownership Type: Product line
- Company Type: Publicly Traded
- Stock Ticker: NYSE: PFE
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Abrysvo | Pfizer Inc. | Product line |
Where to Buy
Disclosure: We may earn commission from purchases
Abrysvo on AmazonHistory of Abrysvo
- Founded: 2023
- Founders: Pfizer Inc. (internal development)
Respiratory syncytial virus was identified as a cause of serious respiratory illness in infants and the elderly in the 1950s, but vaccine development failed for decades. A 1966 trial of an inactivated RSV vaccine worsened disease in children who later encountered the virus, a failure that stalled the field for a generation. The structural characterization of RSV's prefusion F protein in the 2010s provided the target that finally enabled successful vaccines.
Pfizer built Abrysvo on that structural work, developing a bivalent vaccine covering both major RSV subgroups. The phase 3 trials produced efficacy data in older adults and, critically, in pregnant women, where maternal antibody transfer protects newborns during their first months when they are most vulnerable to severe RSV disease.
The FDA approved Abrysvo for adults 60 and older on May 31, 2023, within weeks of the competing GSK vaccine Arexvy. In August 2023, the FDA extended approval to maternal use at 32 through 36 weeks of pregnancy to protect infants from birth through six months, the first maternal RSV vaccine indication. An October 2024 expansion added adults 18 to 59 at increased risk, substantially widening the eligible population.
Abrysvo generated significant revenue in its first full seasons, competing directly with Arexvy and the Moderna RSV vaccine mResvia approved in 2024. The vaccine's maternal indication gives it a distinct market position competitors do not share.
About Pfizer Inc.
What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.
Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.
Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.
Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.
How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.
Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.
What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.
- Founded: 1849
- Headquarters: New York, New York, USA
- Company Type: Publicly Traded
- Stock: NYSE: PFE
- Revenue: $62.6 billion (FY2025)
- Employees: approximately 88,000
Where Is Abrysvo Made / Based?
- Headquarters: New York, New York, USA
- Manufacturing / Operations: United States, Ireland, Belgium
Abrysvo Categories & Tags
Abrysvo Sustainability & Ethics
As a prescription vaccine, Abrysvo is covered by Pfizer's corporate sustainability and access framework rather than product certifications. Pfizer publishes annual sustainability reporting and operates patient access and discount programs covering vaccines.
Maternal immunization has specific ethical dimensions that the vaccine's label addresses through gestational-age restrictions, since the trial established safety within the 32-to-36-week window and a slightly elevated preterm birth signal in some data limited approval to that interval.
Abrysvo Recalls & Controversies
Abrysvo's principal regulatory complication was the preterm birth question. The maternal indication was restricted to weeks 32 through 36 of pregnancy after data raised concerns about a numerical imbalance in preterm births, a limitation competitors and public health bodies have scrutinized. Pfizer maintains monitoring in that population.
Guillain-Barre syndrome has been flagged by regulators as a rare potential risk associated with RSV vaccines in older adults, leading to labeling updates on Abrysvo and Arexvy alike. No product recall has occurred.
Pricing criticism has applied to the adult vaccine launch price, in the range of several hundred dollars per dose, within broader debate over adult vaccine pricing in the commercial market.
Brands Owned by Pfizer Inc.
Healthcare PharmaceuticalsAdcetris
Owned by Pfizer Inc.
Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.
oncologyantibody-drug-conjugatelymphoma
Healthcare PharmaceuticalsCaduet
Owned by Pfizer Inc.
Prescription combination drug containing amlodipine and atorvastatin, co-promoted by Pfizer and developed for simultaneous blood pressure and cholesterol management.
prescription-drugcardiovascularhypertension
Healthcare PharmaceuticalsCelebrex
Owned by Pfizer Inc.
Prescription COX-2 inhibitor anti-inflammatory medication for treating arthritis pain, originally developed by G.D. Searle & Company and now marketed by Pfizer.
pain-reliefanti-inflammatoryarthritis
Healthcare PharmaceuticalsChantix
Owned by Pfizer Inc.
Prescription smoking cessation medication (varenicline) developed by Pfizer, FDA-approved in 2006.
smoking-cessationvareniclinenicotinic-receptor
Healthcare PharmaceuticalsComirnaty
Owned by Pfizer Inc.
Pfizer-BioNTech COVID-19 mRNA vaccine, the first FDA-approved COVID vaccine in the United States, co-commercialized globally by Pfizer and BioNTech.
covid-19mrna-vaccinevaccines
Healthcare PharmaceuticalsDiflucan
Owned by Pfizer Inc.
Prescription antifungal medication (fluconazole) for treating candidiasis, cryptococcal meningitis, and other fungal infections. Developed by Pfizer, FDA-approved in 1990.
antifungalfungal-infectioncandidiasis
Abrysvo Ownership: Pros & Cons
Advantages
- +Wholly owned by Pfizer with no partner split on revenue
- +Maternal immunization indication is a unique market position competitors do not share
- +Younger at-risk adult expansion broadens the addressable population
- +Vaccine infrastructure and retail pharmacy distribution are already established via Prevnar and Comirnaty
Considerations
- -CDC recommendation changes have contracted the routine-use population and complicate forecasting
- -Guillain-Barre labeling risk applies to the RSV vaccine class broadly
- -Arexvy took early share in older adults, the largest single segment
- -Preterm birth restriction limits the maternal label's clinical scope
Frequently Asked Questions About Abrysvo
Sources & Further Reading
Competitors to Abrysvo
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Pfizer | USA | 2020 | Mass market | Global | All Genders |
Learn More About Competitors
Competitive Analysis
Market Positioning: Abrysvo competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Abrysvo
Looking for brands with different ownership structures? These similar brands are not owned by Pfizer Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsBoots
Owned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
pharmacyhealth-beautyuk-retail
Privately Owned
Boots is privately owned, unlike Abrysvo which is under a publicly traded parent company.
Healthcare PharmaceuticalsDuane Reade
Owned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
pharmacydrugstorenew-york
Privately Owned
Duane Reade is privately owned, unlike Abrysvo which is under a publicly traded parent company.
Healthcare PharmaceuticalsPharmacy Direct
Owned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
online-pharmacymail-orderdigital-health
Privately Owned
Pharmacy Direct is privately owned, unlike Abrysvo which is under a publicly traded parent company.
Healthcare PharmaceuticalsRetavase
Owned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
pharmaceuticalthrombolyticreteplase
Privately Owned
Retavase is privately owned, unlike Abrysvo which is under a publicly traded parent company.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Abrysvo which is under a publicly traded parent company.
Healthcare PharmaceuticalsWalgreens
Owned by Walgreens Boots Alliance
Walgreens is the largest U.S. pharmacy retail brand, operating roughly 8,000 stores. It went private in August 2025 under Sycamore Partners as a standalone company.
pharmacydrugstoreretail-pharmacy
Privately Owned
Walgreens is privately owned, unlike Abrysvo which is under a publicly traded parent company.
Pfizer Inc. Stock Information
Jobs at Pfizer Inc.
Latest News About Abrysvo
Related Articles About Abrysvo
View more articles
Industry Analysis
Brands That Relocated Headquarters for Tax Reasons
From Pfizer's failed Irish inversion to ExxonMobil's Texas move, discover why brands relocate their headquarters for tax and legal reasons — and how it affects their brand portfolios. Explore our database.
Who Brands StaffMay 22, 2026
TaxHeadquartersCorporate Relocation
Industry Analysis
How Government Policy Shapes Brand Ownership
From antitrust rulings to tariff wars, government policy determines which brands get acquired, which get blocked, and which stay independent. Our guide explains how policy shapes brand ownership. Explore our database.
Who Brands StaffMay 17, 2026
GovernmentPolicyAntitrust
Brand Comparisons
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
Who Brands StaffMar 16, 2026
PharmaceuticalPfizerJohnson And Johnson
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription
Brandpharmaceutical
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Brand in Healthcare & Pharmaceuticals
thrombolyticstroke-treatment